Our Work
Latham Advises MediWound on US$30 Million Registered Direct Offering of Ordinary Shares
October 6, 2025
Firm represents global leader in next-generation enzymatic therapeutics for tissue repair in the offering.
MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, has announced that it has entered into a definitive securities purchase agreement led by a prominent US-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the Company, par value NIS 0.07 per share, at a purchase price of US$17.30 per share, in a registered direct offering.
The Latham team was led by Tel Aviv partner Gilad Zohari, with London partner Josh Kiernan and New York partner Nate Ajiashvili, and associates Zoey Wu and Amanda Farrish.